Latest & greatest articles for lung cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lung cancer

21. Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): a review of the literature

Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): a review of the literature 30305940 2018 11 14 2059-7029 3 6 2018 ESMO open ESMO Open Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): a review of the literature. e000406 10.1136/esmoopen-2018-000406 Programmed death ligand 1 (PD-L1) targeting immunotherapies, as pembrolizumab and nivolumab, have significantly improved outcome in patients with non-small cell lung (...) cancer (NSCLC). Tobacco smoking is the number one risk factor for lung cancer and is linked to 80%-90% of these cancers. Smoking during cancer therapy may influence on radiotherapy and chemotherapy outcome. We aimed to review the knowledge in immunotherapy. A systematic review was done. We searched for documents and articles published in English language and registered in Cochrane Library, National Health Service (NHS) Centre for Reviews and Dissemination (CRD), Embase or Medline. The search terms

ESMO open2018 Full Text: Link to full Text with Trip Pro

22. Development and Validation of Web-Based Nomograms to Precisely Predict Conditional Risk of Site-Specific Recurrence for Patients With Completely Resected Non-small Cell Lung Cancer: A Multiinstitutional Study

Development and Validation of Web-Based Nomograms to Precisely Predict Conditional Risk of Site-Specific Recurrence for Patients With Completely Resected Non-small Cell Lung Cancer: A Multiinstitutional Study 29758181 2018 09 09 1931-3543 154 3 2018 Sep Chest Chest Development and Validation of Web-Based Nomograms to Precisely Predict Conditional Risk of Site-Specific Recurrence for Patients With Completely Resected Non-small Cell Lung Cancer: A Multiinstitutional Study. 501-511 S0012-3692(18 (...) )30731-1 10.1016/j.chest.2018.04.040 There is currently no consensus regarding the optimal postoperative follow-up strategy for patients with completely resected non-small cell lung cancer (NSCLC). We aimed to develop web-based nomograms to precisely predict site-specific postoperative recurrence in patients with NSCLC and to guide individual surveillance strategies including when to follow up and what diagnostic tests to perform. We investigated the pattern of recurrence in a series of 2,017

EvidenceUpdates2018

23. Gefitinib Mylan - non-small cell lung cancer

Gefitinib Mylan - non-small cell lung cancer Gefitinib Mylan | European Medicines Agency Search Search Menu Gefitinib Mylan gefitinib Table of contents Authorised This medicine is authorised for use in the European Union. Overview Gefitinib Mylan is a cancer medicine used to treat adults who have non-small cell lung cancer that is locally advanced or metastatic (when cancer cells have spread from the original site to other parts of the body). It is used in patients whose cancer cells have (...) on the surface of cancer cells, such as EGFR on the surface of non-small cell lung cancer cells. EGFR is involved in the growth and spread of cancer cells. By blocking EGFR, Gefitinib Mylan helps to slow down the growth and spread of the cancer. Gefitinib Mylan works only in non-small cell lung cancer cells that have a mutation in their EGFR. How has Gefitinib Mylan been studied? Studies on the benefits and risks of the in the authorised use have already been carried out with the reference medicine, Iressa

European Medicines Agency - EPARs2018

24. ASTRO's guideline on Palliative Radiation Therapy for Non-Small Cell Lung Cancer

ASTRO's guideline on Palliative Radiation Therapy for Non-Small Cell Lung Cancer Practical Radiation Oncology Email/Username: Password: Remember me Search Terms Search within Search Share this page: Copyright © 2018 Inc. All rights reserved. | | | | | | The content on this site is intended for health professionals. We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the . Advertisements on this site do not constitute a guarantee

American Society for Radiation Oncology2018

25. Treating EGFR-Mutated Oncogene-Addicted Advanced Non–Small-Cell Lung Cancer in the Era of Economic Crisis in Greece: Challenges and Opportunities

Treating EGFR-Mutated Oncogene-Addicted Advanced Non–Small-Cell Lung Cancer in the Era of Economic Crisis in Greece: Challenges and Opportunities 30260753 2018 12 07 2378-9506 4 2018 Sep Journal of global oncology J Glob Oncol Treating EGFR-Mutated Oncogene-Addicted Advanced Non-Small-Cell Lung Cancer in the Era of Economic Crisis in Greece: Challenges and Opportunities. 1-12 10.1200/JGO.18.00115 Because of the profound financial crisis that commenced in Greece in 2010, severe cuts in health (...) care spending and other restriction measures led to significant delays in the reimbursement of novel antineoplastic agents. In 2011, the Hellenic Society of Medical Oncology initiated a program of early access to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for the treatment of patients with advanced, EGFR-mutant non-small-cell lung cancer (NSCLC). We evaluated treatment patterns and clinical outcomes in patients with EGFR-mutant or wild-type disease treated at a large center

Journal of global oncology2018 Full Text: Link to full Text with Trip Pro

26. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.

Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. BACKGROUND: Standard first-line therapy for metastatic, squamous non-small-cell lung cancer (NSCLC) is platinum-based chemotherapy or pembrolizumab (for patients with programmed death ligand 1 [PD-L1] expression on ≥50% of tumor cells). More recently, pembrolizumab plus chemotherapy was shown to significantly prolong overall survival among patients with nonsquamous NSCLC. METHODS: In this double-blind, phase 3 trial, we (...) randomly assigned, in a 1:1 ratio, 559 patients with untreated metastatic, squamous NSCLC to receive 200 mg of pembrolizumab or saline placebo for up to 35 cycles; all the patients also received carboplatin and either paclitaxel or nanoparticle albumin-bound [nab]-paclitaxel for the first 4 cycles. Primary end points were overall survival and progression-free survival. RESULTS: After a median follow-up of 7.8 months, the median overall survival was 15.9 months (95% confidence interval [CI], 13.2

NEJM2018

27. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. BACKGROUND: Enhancing tumor-specific T-cell immunity by inhibiting programmed death ligand 1 (PD-L1)-programmed death 1 (PD-1) signaling has shown promise in the treatment of extensive-stage small-cell lung cancer. Combining checkpoint inhibition with cytotoxic chemotherapy may have a synergistic effect and improve efficacy. METHODS: We conducted this double-blind, placebo-controlled, phase 3 trial to evaluate (...) atezolizumab plus carboplatin and etoposide in patients with extensive-stage small-cell lung cancer who had not previously received treatment. Patients were randomly assigned in a 1:1 ratio to receive carboplatin and etoposide with either atezolizumab or placebo for four 21-day cycles (induction phase), followed by a maintenance phase during which they received either atezolizumab or placebo (according to the previous random assignment) until they had unacceptable toxic effects, disease progression

NEJM2018

28. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.

Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. BACKGROUND: Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, has robust efficacy in patients with ALK-positive non-small-cell lung cancer (NSCLC) that is refractory to crizotinib. The efficacy of brigatinib, as compared with crizotinib, in patients with advanced ALK-positive NSCLC who have not previously received an ALK inhibitor is unclear. METHODS: In an open-label, phase 3 trial, we randomly

NEJM2018

29. Tumor evolution in non-small-cell lung cancer

Tumor evolution in non-small-cell lung cancer 30345083 2018 10 22 2059-7029 3 6 2018 ESMO open ESMO Open Tumor evolution in non-small-cell lung cancer. e000436 10.1136/esmoopen-2018-000436 Parry Marina M BMJ Publishing Group, London, UK. eng Journal Article 2018 09 25 England ESMO Open 101690685 2059-7029 podcast Competing interests: None declered. 2018 08 16 2018 08 16 2018 10 23 6 0 2018 10 23 6 0 2018 10 23 6 1 epublish 30345083 10.1136/esmoopen-2018-000436 esmoopen-2018-000436 PMC6190228

ESMO open2018 Full Text: Link to full Text with Trip Pro

30. Virtual reality‐assisted localization and three‐dimensional printing‐enhanced multidisciplinary decision to treat radiologically occult superficial endobronchial lung cancer

Virtual reality‐assisted localization and three‐dimensional printing‐enhanced multidisciplinary decision to treat radiologically occult superficial endobronchial lung cancer 30253072 2018 12 07 1759-7714 9 11 2018 Nov Thoracic cancer Thorac Cancer Virtual reality-assisted localization and three-dimensional printing-enhanced multidisciplinary decision to treat radiologically occult superficial endobronchial lung cancer. 1525-1527 10.1111/1759-7714.12879 Herein, we report the unique case (...) of a 75-year-old male patient who had undergone a left upper lobectomy for lung cancer and developed an incidental superficial endobronchial squamous cell carcinoma in the right upper lobe that was not localizable on modern cross-sectional imaging modalities. The superficial endobronchial squamous cell carcinoma was successfully localized by computed tomography-driven virtual reality endoscopy and was identically matched with a small, whitish, patch lesion on bronchoscopy. The localized lesion

Thoracic cancer2018 Full Text: Link to full Text with Trip Pro

31. Real‐world EGFR testing in patients with stage IIIB/IV non‐small‐cell lung cancer in North China: A multicenter, non‐interventional study

Real‐world EGFR testing in patients with stage IIIB/IV non‐small‐cell lung cancer in North China: A multicenter, non‐interventional study 30253083 2018 12 07 1759-7714 9 11 2018 Nov Thoracic cancer Thorac Cancer Real-world EGFR testing in patients with stage IIIB/IV non-small-cell lung cancer in North China: A multicenter, non-interventional study. 1461-1469 10.1111/1759-7714.12859 Before tyrosine kinase inhibitor (TKI) therapy can be administered in patients with advanced non-small (...) cell lung cancer (NSCLC), EGFR mutation testing is required. However, few studies have evaluated the extent of EGFR testing in real-world practice in China. A multicenter, observational study of EGFR testing in NSCLC patients in North China was conducted. Treatment-naïve patients or those with postoperative recurrent stage IIIB/IV NSCLC were enrolled. The primary objective was EGFR testing rate. Secondary objectives included EGFR mutation status, EGFR testing methods and specimens, factors

Thoracic cancer2018 Full Text: Link to full Text with Trip Pro

32. Pleural or pericardial metastasis: A significant factor affecting efficacy and adverse events in lung cancer patients treated with PD‐1/PD‐L1 inhibitors

Pleural or pericardial metastasis: A significant factor affecting efficacy and adverse events in lung cancer patients treated with PD‐1/PD‐L1 inhibitors 30253080 2018 12 07 1759-7714 9 11 2018 Nov Thoracic cancer Thorac Cancer Pleural or pericardial metastasis: A significant factor affecting efficacy and adverse events in lung cancer patients treated with PD-1/PD-L1 inhibitors. 1500-1508 10.1111/1759-7714.12877 Immunotherapy is a new paradigm for the treatment of non-small-cell lung cancer (...) (NSCLC), and targeting the PD-1 or PD-L1 pathway is a promising therapeutic option. Although PD-1/PD-L1 inhibitors are more effective than standard chemotherapy in lung cancer, clinicians are afraid to actively use them because of hyperprogression and pseudoprogression. The aim of this study was to investigate the factors associated with tumor response and serious outcomes. We retrospectively collected the medical records of 51 patients with advanced NSCLC who received PD-1/PD-L1 inhibitors between

Thoracic cancer2018 Full Text: Link to full Text with Trip Pro

33. Low pre‐treatment nutritional index is significantly related to poor outcomes in small cell lung cancer

Low pre‐treatment nutritional index is significantly related to poor outcomes in small cell lung cancer 30209884 2018 12 07 1759-7714 9 11 2018 Nov Thoracic cancer Thorac Cancer Low pre-treatment nutritional index is significantly related to poor outcomes in small cell lung cancer. 1483-1491 10.1111/1759-7714.12862 The importance of nutritional status and chronic inflammation has been emphasized in cancer. We investigated the impact of Onodera's prognostic nutritional index (OPNI) on clinical (...) outcomes in small cell lung cancer (SCLC) patients. Data from 220 SCLC patients treated with first-line platinum-based chemotherapy from 2006 to 2017 were retrospectively reviewed. The OPNI was calculated as 10 × serum albumin level (g/dL) + 0.005 × absolute lymphocyte count (/mm 3 ). Patients with an OPNI of > 45, 40-45, or < 40 were categorized in high, intermediate, or low OPNI groups, respectively. The proportion of non-responders to first-line therapy increased as the OPNI decreased (high

Thoracic cancer2018 Full Text: Link to full Text with Trip Pro

34. Comparable immunoreactivity rates of PD‐L1 in archival and recent specimens from non‐small cell lung cancer

Comparable immunoreactivity rates of PD‐L1 in archival and recent specimens from non‐small cell lung cancer 30209885 2018 12 07 1759-7714 9 11 2018 Nov Thoracic cancer Thorac Cancer Comparable immunoreactivity rates of PD-L1 in archival and recent specimens from non-small cell lung cancer. 1476-1482 10.1111/1759-7714.12861 Molecular targeted therapy including the use of monoclonal antibodies directed against the immune checkpoints PD-L1 and PD-1 receptor have remarkably improved (...) the therapeutic response and survival of cancer patients. The tumor expression level of PD-L1 can predict the response rate to checkpoint inhibitors. We evaluated whether the time interval between tumor tissue sampling/paraffinization and immunohistochemistry affects the staining level of PD-L1 in non-small cell lung cancer (NSCLC). This study comprised 137 patients with NSCLC. Tumors were stained with 22C3 or 28-8 antibodies. There was a significant correlation between the immunoreactivity rate of tumor

Thoracic cancer2018 Full Text: Link to full Text with Trip Pro

35. Immune checkpoint inhibitors for every patient with non-small cell lung cancer? Update on immunotherapy in patients with lung cancer

Immune checkpoint inhibitors for every patient with non-small cell lung cancer? Update on immunotherapy in patients with lung cancer 30345082 2018 10 22 2059-7029 3 6 2018 ESMO open ESMO Open Immune checkpoint inhibitors for every patient with non-small cell lung cancer? Update on immunotherapy in patients with lung cancer. e000429 10.1136/esmoopen-2018-000429 Vansteenkiste Johan F JF Respiratory Oncology Unit and Trial Unit, Department of Respiratory Diseases, University Hospitals KU Leuven

ESMO open2018 Full Text: Link to full Text with Trip Pro

36. Quantitative proteomic analysis of mitochondrial proteins differentially expressed between small cell lung cancer cells and normal human bronchial epithelial cells

Quantitative proteomic analysis of mitochondrial proteins differentially expressed between small cell lung cancer cells and normal human bronchial epithelial cells 30198174 2018 12 07 1759-7714 9 11 2018 Nov Thoracic cancer Thorac Cancer Quantitative proteomic analysis of mitochondrial proteins differentially expressed between small cell lung cancer cells and normal human bronchial epithelial cells. 1366-1375 10.1111/1759-7714.12839 Small cell lung cancer (SCLC) is highly aggressive (...) and is associated with a dismal prognosis. However, there are no clinically recognized biomarkers for early diagnosis. In this study, we used quantitative proteomics to build differential mitochondrial protein profiles that may be used for early diagnosis and investigated the pathogenesis of lung cancer. We cultured SCLC cells (NCI-H446) and normal human bronchial epithelial cells (16-HBE); mitochondria were extracted and purified using differential and Percoll density gradient centrifugation. Subsequently, we

Thoracic cancer2018 Full Text: Link to full Text with Trip Pro

37. Extra cost of brain metastases (BM) in patients with non-squamous non-small cell lung cancer (NSCLC): a French national hospital database analysis

Extra cost of brain metastases (BM) in patients with non-squamous non-small cell lung cancer (NSCLC): a French national hospital database analysis 30233822 2018 11 14 2059-7029 3 6 2018 ESMO open ESMO Open Extra cost of brain metastases (BM) in patients with non-squamous non-small cell lung cancer (NSCLC): a French national hospital database analysis. e000414 10.1136/esmoopen-2018-000414 To assess the incremental cost associated with the management of patients with primary non-squamous non (...) -small cell lung cancer (NSCLC) with brain metastases at the time of diagnosis. Data were extracted from the French Hospital medical information database (Programme de Médicalisation des Systèmes d'Information (PMSI)). Patients with non-squamous NSCLC were identified through a diagnosis of lung cancer and a prescription of bevacizumab or pemetrexed. All such patients hospitalised with lung cancer for the first time in 2013 and with metastases identified at the first hospitalisation were eligible. Two

ESMO open2018 Full Text: Link to full Text with Trip Pro

38. Temporal Trends and Geographic Patterns of Lung Cancer Incidence by Histology in Thailand, 1990 to 2014

Temporal Trends and Geographic Patterns of Lung Cancer Incidence by Histology in Thailand, 1990 to 2014 30192698 2018 12 07 2378-9506 4 2018 Aug Journal of global oncology J Glob Oncol Temporal Trends and Geographic Patterns of Lung Cancer Incidence by Histology in Thailand, 1990 to 2014. 1-29 10.1200/JGO.18.00013 Purpose Lung cancer is one of the most common cancers worldwide and in Thailand. We characterize and forecast region-specific patterns of lung cancer incidence by histology and sex (...) . Methods We analyzed lung cancer incidence trends in Thailand by histology (adenocarcinoma [AdC]; squamous cell carcinoma [SCC]; and large-cell, small-cell, and other carcinomas) from 1990 to 2014 in four cancer registries in three regions (north, Chiang Mai Province and Lampang Province; northeast: Khon Kaen Province; south: Songkhla Province). Annual percent change (APC) was calculated to quantify the incidence rate trends using joinpoint regression. Age-period-cohort models were used to examine

Journal of global oncology2018 Full Text: Link to full Text with Trip Pro

39. New drugs in thoracic oncology: needs and knowledge – an online ERS Lung Cancer Assembly survey

New drugs in thoracic oncology: needs and knowledge – an online ERS Lung Cancer Assembly survey 30186846 2018 11 14 2312-0541 4 3 2018 Jul ERJ open research ERJ Open Res New drugs in thoracic oncology: needs and knowledge - an online ERS Lung Cancer Assembly survey. 00040-2018 10.1183/23120541.00040-2018 In the last decade, systemic therapy for advanced lung cancer has become diverse, complex and personalised. These new therapies (monoclonal antibodies, tyrosine kinase inhibitors (TKIs (...) in an online platform reporting new drugs' toxicities. Despite a large amount of publicity and integration of new drugs into therapeutic algorithms and clinical guidelines, physicians taking care of lung cancer patients have a need for up-to-date information on systemic therapy toxicity management and legal constraints. Berghmans Thierry T Dept of Intensive Care, and Oncological Emergencies and Thoracic Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. Evison Matthew M

ERJ open research2018 Full Text: Link to full Text with Trip Pro

40. Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer

Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer 29906251 2018 08 16 1527-7755 36 23 2018 Aug 10 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small (...) -Cell Lung Cancer. 2386-2394 10.1200/JCO.2018.77.7672 Purpose Both temozolomide (TMZ) and poly (ADP-ribose) polymerase (PARP) inhibitors are active in small-cell lung cancer (SCLC). This phase II, randomized, double-blind study evaluated whether addition of the PARP inhibitor veliparib to TMZ improves 4-month progression-free survival (PFS). Patients and Methods A total of 104 patients with recurrent SCLC were randomly assigned 1:1 to oral veliparib or placebo 40 mg twice daily, days 1 to 7

EvidenceUpdates2018 Full Text: Link to full Text with Trip Pro